BBIO - BridgeBio Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Palo Alto,
United States
Type: Equity
BBIO price evolution
BBIO
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $392.59 | $521.87 | $322.37 | $432.87 |
| Short term investments | $58.95 | $38.05 | $81.36 | $83.92 |
| Net receivables | $1.75 | $5.17 | $8.61 | $10.76 |
| Inventory | ||||
| Total current assets | $477.59 | $587.67 | $432.88 | $552.7 |
| Long term investments | ||||
| Property, plant & equipment | $19.84 | $21.75 | $22.86 | $24.1 |
| Goodwill & intangible assets | $26.32 | $26.92 | $27.52 | $28.11 |
| Total noncurrent assets | $68.79 | $67.34 | $70.78 | $72.98 |
| Total investments | $58.95 | $38.05 | $81.36 | $83.92 |
| Total assets | $546.38 | $655.01 | $503.66 | $625.68 |
| Current liabilities | ||||
| Accounts payable | $10.65 | $4.47 | $3.87 | $4.08 |
| Deferred revenue | $6.1 | $6.59 | $6.21 | $6.67 |
| Short long term debt | $4.13 | $4.14 | $3.78 | $3.67 |
| Total current liabilities | $143.84 | $106.06 | $110.12 | $96.6 |
| Long term debt | $1735.71 | $1730.89 | $1729.85 | $1725.2 |
| Total noncurrent liabilities | $1745.07 | $1742.68 | $1743.18 | $1742.7 |
| Total debt | $1739.84 | $1735.03 | $1733.63 | $1728.87 |
| Total liabilities | $1888.91 | $1848.74 | $1853.3 | $1839.29 |
| Shareholders' equity | ||||
| Retained earnings | -$2560.5 | -$2392.35 | -$2215.35 | -$2057.45 |
| Other shareholder equity | $0.03 | $0.03 | $0.06 | -$0.01 |
| Total shareholder equity | -$1354.26 | -$1207.54 | -$1362.02 | -$1225.66 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $392.59 | $414.62 | $393.77 | $356.08 |
| Short term investments | $58.95 | $95.23 | $442.89 | $251.01 |
| Net receivables | $1.75 | $17.08 | $19.75 | |
| Inventory | ||||
| Total current assets | $477.59 | $548.85 | $888.86 | $642.82 |
| Long term investments | ||||
| Property, plant & equipment | $19.84 | $25.25 | $45.97 | $36.83 |
| Goodwill & intangible assets | $26.32 | $28.71 | $44.93 | |
| Total noncurrent assets | $68.79 | $74.18 | $123.93 | $60.76 |
| Total investments | $58.95 | $95.23 | $442.89 | $251.01 |
| Total assets | $546.38 | $623.04 | $1012.79 | $703.59 |
| Current liabilities | ||||
| Accounts payable | $10.65 | $11.56 | $11.88 | $8.95 |
| Deferred revenue | $6.1 | $8.16 | ||
| Short long term debt | $4.13 | $3.67 | $4.94 | $5.25 |
| Total current liabilities | $143.84 | $121.43 | $135.07 | $95.65 |
| Long term debt | $1735.71 | $1707.62 | $1721.23 | $490.53 |
| Total noncurrent liabilities | $1745.07 | $1746.53 | $1743.3 | $500.05 |
| Total debt | $1739.84 | $1723.56 | $1726.17 | $495.79 |
| Total liabilities | $1888.91 | $1877.65 | $1878.37 | $595.7 |
| Shareholders' equity | ||||
| Retained earnings | -$2560.5 | -$1918.15 | -$1436.97 | -$888.75 |
| Other shareholder equity | $0.03 | -$0.33 | -$0.13 | $0.19 |
| Total shareholder equity | -$1354.26 | -$1254.62 | -$870.41 | $57.91 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.75 | $4.09 | $1.64 | $1.83 |
| Cost of revenue | $0.6 | $0.6 | $0.6 | $0.65 |
| Gross Profit | $1.15 | $3.49 | $1.04 | $1.18 |
| Operating activities | ||||
| Research & development | $130.23 | $125.14 | $107.49 | $92.86 |
| Selling, general & administrative | $47.58 | $35.78 | $36.12 | $31.11 |
| Total operating expenses | $178.56 | $161.19 | $147.14 | $127.34 |
| Operating income | -$177.42 | -$157.69 | -$146.1 | -$126.16 |
| Income from continuing operations | ||||
| EBIT | -$147.88 | -$156.69 | -$137.31 | -$120.03 |
| Income tax expense | ||||
| Interest expense | $20.27 | $20.31 | $20.59 | $20.12 |
| Net income | ||||
| Net income | -$168.15 | -$177 | -$157.9 | -$140.16 |
| Income (for common shares) | -$168.15 | -$177 | -$157.9 | -$140.16 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.3 | $77.65 | $69.72 | $8.25 |
| Cost of revenue | $2.45 | $3.43 | $3.11 | |
| Gross Profit | $6.86 | $74.21 | $66.6 | $8.25 |
| Operating activities | ||||
| Research & development | $455.71 | $399.46 | $451.02 | $337.05 |
| Selling, general & administrative | $150.59 | $143.19 | $192.21 | $145.68 |
| Total operating expenses | $614.23 | $586.42 | $643.23 | $482.73 |
| Operating income | -$607.37 | -$512.2 | -$576.63 | -$474.48 |
| Income from continuing operations | ||||
| EBIT | -$561.91 | -$400.75 | -$515.76 | -$412.07 |
| Income tax expense | ||||
| Interest expense | $81.29 | $80.44 | $46.78 | $36.66 |
| Net income | ||||
| Net income | -$643.2 | -$481.18 | -$562.54 | -$448.72 |
| Income (for common shares) | -$643.2 | -$481.18 | -$562.54 | -$448.72 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$168.15 | -$177 | -$157.9 | -$140.16 |
| Operating activities | ||||
| Depreciation | $2.59 | $2.64 | $2.63 | $2.67 |
| Business acquisitions & disposals | -$0.5 | |||
| Stock-based compensation | $37.02 | $22.6 | $27.18 | $21.91 |
| Total cash flows from operations | -$124.82 | -$145.23 | -$113.35 | -$144.32 |
| Investing activities | ||||
| Capital expenditures | -$0.43 | -$0.43 | -$0.43 | -$0.01 |
| Investments | $0.37 | $38.11 | $4.55 | $12.81 |
| Total cash flows from investing | -$0.07 | $37.68 | $4.12 | $12.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$3.01 | $305.19 | -$0.17 | $144.31 |
| Net borrowings | ||||
| Total cash flows from financing | -$4.52 | $307.04 | -$1.23 | $150.25 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$129.41 | $199.5 | -$110.47 | $18.23 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$643.2 | -$481.18 | -$562.54 | -$448.72 |
| Operating activities | ||||
| Depreciation | $10.53 | $11.94 | $11.45 | $3.09 |
| Business acquisitions & disposals | -$0.5 | $10 | $13.65 | -$6.91 |
| Stock-based compensation | $108.71 | $91.56 | $99.5 | $58.46 |
| Total cash flows from operations | -$527.72 | -$419.49 | -$497.93 | -$399.71 |
| Investing activities | ||||
| Capital expenditures | -$1.31 | $105.18 | -$13.25 | -$7.37 |
| Investments | $55.84 | $339.47 | -$166.23 | -$38.72 |
| Total cash flows from investing | $54.03 | $453.15 | -$200.83 | -$52.99 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $446.33 | $5.85 | -$200.93 | -$74.51 |
| Net borrowings | -$20.49 | $1063.61 | $536.96 | |
| Total cash flows from financing | $451.54 | -$13.13 | $736.45 | $447.19 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.15 | $20.52 | $37.69 | -$5.52 |
News
|
BridgeBio Pharma launches $250 million stock offering
Investing.com
3 Mar 2024
|
|
BridgeBio Pharma launches $250 million stock offering
Investing.com
3 Mar 2024
|
|
BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials
GuruFocus.com via Yahoo Finance
22 Feb 2024
|
|
BridgeBio Pharma Inc Director Hannah Valantine Sells 2,915 Shares
GuruFocus.com via Yahoo Finance
17 Jan 2024
|
|
Insider Sell Alert: BridgeBio Pharma Inc's Brian Stephenson Unloads 22,685 Shares
GuruFocus.com via Yahoo Finance
21 Nov 2023
|
|
What’s Up The Most This Year? Cipher Mining And Carvana
Forbes
6 Nov 2023
|
|
Estimating The Fair Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Simply Wall St. via Yahoo Finance
4 Nov 2023
|
|
BridgeBio Pharma Inc (BBIO) Reports Q3 2023 Financial Results
GuruFocus.com via Yahoo Finance
2 Nov 2023
|
|
Expert Perspectives on Biggest Court Cases
Law.com
16 Aug 2023
|
|
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Zacks via Yahoo Finance
15 Aug 2023
|
Fundamentals
| Market cap | $4.43B |
|---|---|
| Enterprise value | $5.78B |
| Shares outstanding | 173.97M |
| Revenue | $9.30M |
|---|---|
| EBITDA | -$551.39M |
| EBIT | -$561.91M |
| Net Income | -$643.20M |
| Revenue Q/Q | -6.68% |
| Revenue Y/Y | -88.02% |
| P/E ratio | -6.89 |
|---|---|
| EV/Sales | 620.92 |
| EV/EBITDA | -10.48 |
| EV/EBIT | -10.28 |
| P/S ratio | 476.10 |
| P/B ratio | -3.27 |
| Book/Share | -7.78 |
| Cash/Share | 2.26 |
| EPS | -$3.70 |
|---|---|
| ROA | -110.39% |
| ROE | 49.96% |
| Debt/Equity | -1.39 |
|---|---|
| Net debt/EBITDA | -2.71 |
| Current ratio | 3.32 |
| Quick ratio | 3.32 |